Splice Variants CLDN18.2 and FGFR2b Emerge as Prime Cancer Drug Targets
A new review maps how two splice-variant proteins, CLDN18.2 and FGFR2b, became leading cancer drug targets, and why next-generation antibodies, ...
A new review maps how two splice-variant proteins, CLDN18.2 and FGFR2b, became leading cancer drug targets, and why next-generation antibodies, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine